Pub Date : 2016-11-08DOI: 10.5455/BCP.20160207082039
Z. Ozturk, E. Olmez, T. Gurpinar, S. Gok, K. Vural
Objective: The question of harmfulness of the psychiatric drugs creates a major dilemma for pregnant women. The risks associated with prenatal psychotropic drug exposure are often overestimated. It...
目的:精神科药物的危害问题是困扰孕妇的一大难题。与产前精神药物暴露相关的风险往往被高估。它……
{"title":"Safety of psychotropic medications in pregnancy: an observational cohort study -","authors":"Z. Ozturk, E. Olmez, T. Gurpinar, S. Gok, K. Vural","doi":"10.5455/BCP.20160207082039","DOIUrl":"https://doi.org/10.5455/BCP.20160207082039","url":null,"abstract":"Objective: The question of harmfulness of the psychiatric drugs creates a major dilemma for pregnant women. The risks associated with prenatal psychotropic drug exposure are often overestimated. It...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74104105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20150825013656
E. Tüzün
Cell surface antibody—associated central nervous system disorders have emerged in the last decade as a novel field in neuroimmunology. It is now well known that patients with antibodies to ion chan...
{"title":"Autoantibodies to Neurotransmitter Receptors and Ion Channels in Psychotic Disorders","authors":"E. Tüzün","doi":"10.5455/BCP.20150825013656","DOIUrl":"https://doi.org/10.5455/BCP.20150825013656","url":null,"abstract":"Cell surface antibody—associated central nervous system disorders have emerged in the last decade as a novel field in neuroimmunology. It is now well known that patients with antibodies to ion chan...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74638876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20151202102254
M. Cvjetković-Bošnjak, B. Soldatović-Stajić, S. Babović, V. Sakač
ABSTRACTObjective: The aim of this research was to determine whether statistically significant differences exist in the clinical presentation (symptoms) of depressive disorders in men and women and, if so, what are they reflected in.Material and Method: The study included 150 patients between the ages of 18 and 65 who have been hospitalized due to a major depressive disorder according to the diagnostic criteria of DSM-IV classification, at the Psychiatric Clinic in Novi Sad, Serbia. Patients with comorbid physical or other mental disorders were not included. Within the research process, during the first day of hospitalization, the Hamilton Depression Rating Scale with 21 items was administered, while 12 other symptoms of depression (specific quality of the depression, pessimism, stability of depression to environmental influences, ideas of impoverishment, worthlessness, blaming of others, social isolation, anhedonia, monoideism, self-pity, dependence on others, and manipulativeness) were assessed using th...
{"title":"Gender Differences in Depressive Symptoms Among Inpatients","authors":"M. Cvjetković-Bošnjak, B. Soldatović-Stajić, S. Babović, V. Sakač","doi":"10.5455/BCP.20151202102254","DOIUrl":"https://doi.org/10.5455/BCP.20151202102254","url":null,"abstract":"ABSTRACTObjective: The aim of this research was to determine whether statistically significant differences exist in the clinical presentation (symptoms) of depressive disorders in men and women and, if so, what are they reflected in.Material and Method: The study included 150 patients between the ages of 18 and 65 who have been hospitalized due to a major depressive disorder according to the diagnostic criteria of DSM-IV classification, at the Psychiatric Clinic in Novi Sad, Serbia. Patients with comorbid physical or other mental disorders were not included. Within the research process, during the first day of hospitalization, the Hamilton Depression Rating Scale with 21 items was administered, while 12 other symptoms of depression (specific quality of the depression, pessimism, stability of depression to environmental influences, ideas of impoverishment, worthlessness, blaming of others, social isolation, anhedonia, monoideism, self-pity, dependence on others, and manipulativeness) were assessed using th...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75702112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20151209125410
K. Baskoy, S. Ay, F. Deniz, A. Yonem
We have read with great interest the article “Relationship between plasma levels of prolactin and the severity of negative symptoms in patients with schizophrenia” written by Ates et al.. They aimed to investigate the relationship between prolactin levels of plasma and negative symptoms in patients with schizophrenia. They demonstrated that prolactin levels are positively correlated with the severity of negative symptoms. We would like to thank to the authors for their contribution of the present study, which is successfully designed and documented. In Ates et al’s article, the authors mentioned that gonadal steroids could play a significant role in the pathophysiology and could affect the course of schizophrenia. Additionally, it is known as classically, hyperprolactinemia is associated with disturbances in the levels of key reproductive hormones. For instance, Hyperprolactinemia inhibiting the effect of FSH and LH could decrease the levels of testosterone and estradiol. Although, there is a relationship between gonadal s t e r o i d s a n d b o t h h y p e r p r o l a c t i n e m i a a n d schizophrenia, researchers in this study did not consider the levels of testosterone, estradiol, FSH, and LH. Hence, the results might be different if the authors had mentioned those factors in their study. Prolactin exists in different forms in circulation as monomeric, dimeric, and polymeric. While the monomeric form, defined biologically active, constitutes the majority of total prolactin; the polymeric form defined macroprolactin and accepted biologically inactive is a complex of monomeric p r o l a c t i n w i t h I g G . M a c r o p r o l a c t i n e m i a i s characterized by excess of macroprolactin levels and seen 10-25% in patients with hyperprolactinaemia. This condition does not require any treatment, since it is not clinically significant. Another important issue in the differential diagnosis of hyperprolactinemia is to investigate the drug induced hyperprolactinemia such as metoclopramide, domperidone, and verapamil. This situation is quite often seen in clinical practice. Therefore, establishing of macroprolactinemia and drugs increasing the prolactin levels is quite important to avoid the misdiagnosis and overtreatments in patients with hyperprolactinemia. In conclusion, it is a pleasure for us to see that physicians not primarily involved in endocrinology field are also aware of hyperprolactinemia and its association with psychiatric disorders and medications. So, it would have been better if these additional crucial factors were included in the paper.
我们饶有兴趣地阅读了Ates等人的文章《精神分裂症患者血浆催乳素水平与阴性症状严重程度的关系》。他们的目的是研究精神分裂症患者血浆催乳素水平与阴性症状之间的关系。他们证明催乳素水平与阴性症状的严重程度呈正相关。我们要感谢作者对本研究的贡献，这是成功的设计和记录。在Ates等人的文章中，作者提到性腺类固醇在病理生理中发挥重要作用，并可能影响精神分裂症的病程。此外，众所周知，高催乳素血症与关键生殖激素水平的紊乱有关。例如，高催乳素血症抑制FSH和LH的作用，可以降低睾酮和雌二醇的水平。虽然，性腺激素水平与抑郁症、抑郁症和精神分裂症之间存在一定的关系，但研究人员在本研究中并未考虑睾酮、雌二醇、卵泡刺激素和黄体生成素的水平。因此，如果作者在他们的研究中提到这些因素，结果可能会有所不同。催乳素以不同的形式存在于循环中，有单体、二聚体和聚合物。虽然被定义为生物活性的单体形式构成了总催乳素的大部分;定义的聚合形式macroprolactin并接受生物活性是一个复杂的单体的p r l c o t我n w t h g g。高泌乳素血症患者中有10-25%的高泌乳素血症患者以高泌乳素血症为特征。这种情况不需要任何治疗，因为它没有临床意义。高催乳素血症鉴别诊断的另一个重要问题是探讨药物引起的高催乳素血症，如甲氧氯普胺、多潘立酮和维拉帕米。这种情况在临床实践中很常见。因此，建立高催乳素血症和提高催乳素水平的药物对于避免高催乳素血症患者的误诊和过度治疗是非常重要的。总之，我们很高兴地看到，不是主要从事内分泌学领域的医生也意识到高泌乳素血症及其与精神疾病和药物的关系。因此，如果这些额外的关键因素包括在论文中，那就更好了。
{"title":"Hyperprolactinemia is a Major Problem in Patients Treated with Antipsychotic Drugs","authors":"K. Baskoy, S. Ay, F. Deniz, A. Yonem","doi":"10.5455/BCP.20151209125410","DOIUrl":"https://doi.org/10.5455/BCP.20151209125410","url":null,"abstract":"We have read with great interest the article “Relationship between plasma levels of prolactin and the severity of negative symptoms in patients with schizophrenia” written by Ates et al.. They aimed to investigate the relationship between prolactin levels of plasma and negative symptoms in patients with schizophrenia. They demonstrated that prolactin levels are positively correlated with the severity of negative symptoms. We would like to thank to the authors for their contribution of the present study, which is successfully designed and documented. In Ates et al’s article, the authors mentioned that gonadal steroids could play a significant role in the pathophysiology and could affect the course of schizophrenia. Additionally, it is known as classically, hyperprolactinemia is associated with disturbances in the levels of key reproductive hormones. For instance, Hyperprolactinemia inhibiting the effect of FSH and LH could decrease the levels of testosterone and estradiol. Although, there is a relationship between gonadal s t e r o i d s a n d b o t h h y p e r p r o l a c t i n e m i a a n d schizophrenia, researchers in this study did not consider the levels of testosterone, estradiol, FSH, and LH. Hence, the results might be different if the authors had mentioned those factors in their study. Prolactin exists in different forms in circulation as monomeric, dimeric, and polymeric. While the monomeric form, defined biologically active, constitutes the majority of total prolactin; the polymeric form defined macroprolactin and accepted biologically inactive is a complex of monomeric p r o l a c t i n w i t h I g G . M a c r o p r o l a c t i n e m i a i s characterized by excess of macroprolactin levels and seen 10-25% in patients with hyperprolactinaemia. This condition does not require any treatment, since it is not clinically significant. Another important issue in the differential diagnosis of hyperprolactinemia is to investigate the drug induced hyperprolactinemia such as metoclopramide, domperidone, and verapamil. This situation is quite often seen in clinical practice. Therefore, establishing of macroprolactinemia and drugs increasing the prolactin levels is quite important to avoid the misdiagnosis and overtreatments in patients with hyperprolactinemia. In conclusion, it is a pleasure for us to see that physicians not primarily involved in endocrinology field are also aware of hyperprolactinemia and its association with psychiatric disorders and medications. So, it would have been better if these additional crucial factors were included in the paper.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80694317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20151221101229
A. Adanır
{"title":"Priapism Associated with Aripiprazole and Quetiapine in an 8-Year-Old Boy with Autism","authors":"A. Adanır","doi":"10.5455/BCP.20151221101229","DOIUrl":"https://doi.org/10.5455/BCP.20151221101229","url":null,"abstract":"","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77822897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20150908025240
B. Lee
ABSTRACTAttention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by various comorbid conditions including mood instability, personality problems, and addiction disorders, and ADHD-like features may also be an early vulnerability marker for schizophrenia. Because of these comorbidities, drug combination treatments and drug-drug interactions are becoming more important. Aripiprazole is an atypical antipsychotic medication with unique properties including dopamine D2 (D2) receptor partial agonism. The intrinsic activity of aripiprazole may serve as a basis for understanding why it can achieve a considerably higher degree of D2 receptor occupancy without causing the extrapyramidal side effects commonly seen with D2 receptor full antagonists and why clinicians may sometimes see aggravation of psychotic symptoms when they switch a patient from D2 full antagonists to aripiprazole. The present case report cautiously suggests the possible value of aripiprazole's stabilizing ef...
{"title":"Aripiprazole Treatment in a Patient with Schizophrenia and Severe Antipsychotic-Induced Parkinsonism Following Long-Term use of Methylphenidate: A Case Report","authors":"B. Lee","doi":"10.5455/BCP.20150908025240","DOIUrl":"https://doi.org/10.5455/BCP.20150908025240","url":null,"abstract":"ABSTRACTAttention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by various comorbid conditions including mood instability, personality problems, and addiction disorders, and ADHD-like features may also be an early vulnerability marker for schizophrenia. Because of these comorbidities, drug combination treatments and drug-drug interactions are becoming more important. Aripiprazole is an atypical antipsychotic medication with unique properties including dopamine D2 (D2) receptor partial agonism. The intrinsic activity of aripiprazole may serve as a basis for understanding why it can achieve a considerably higher degree of D2 receptor occupancy without causing the extrapyramidal side effects commonly seen with D2 receptor full antagonists and why clinicians may sometimes see aggravation of psychotic symptoms when they switch a patient from D2 full antagonists to aripiprazole. The present case report cautiously suggests the possible value of aripiprazole's stabilizing ef...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77071001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20151219072235
F. Arslan, Demet Sağlam Aykut, C. İnce, A. Tiryaki
Antipsychotic drugs can cause neutropenia which can progress to life-threatening agranulocytosis. Clozapine is well-known for this side effect which is rare for other antipsychotics. Quetiapine is ...
{"title":"Neutropenia and Thrombocytopenia Induced By Quetiapine Monotherapy: A Case Report and Review of Literature","authors":"F. Arslan, Demet Sağlam Aykut, C. İnce, A. Tiryaki","doi":"10.5455/BCP.20151219072235","DOIUrl":"https://doi.org/10.5455/BCP.20151219072235","url":null,"abstract":"Antipsychotic drugs can cause neutropenia which can progress to life-threatening agranulocytosis. Clozapine is well-known for this side effect which is rare for other antipsychotics. Quetiapine is ...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74948463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20151216022322
H. Eş, I. Melez, Ayse Ozgun, D. O. Melez, Ç. Kertmen, M. Cavlak
ABSTRACTEosinophilic myocarditis is a rare cause of sudden unexpected death and characterized by eosinophilic infiltration in the myocardium. Clozapine is among the agents that can cause eosinophilic myocarditis. Our case is a 48 year-old female patient who was hospitalized in psychiatry inpatient unit and died unexpectedly on the 35th day of her hospitalization while on clozapine treatment. Even though the autopsy revealed an increased heart weight, fatty streaks on aorta, and thickening of epicardial fat tissue macroscopically, no pathological macroscopic features were noted in the myocardial cross sections. Eosinophilic myocarditis findings were found in the histopathological evaluation. Toxicological assessment revealed presence of clozapine in the blood (735ng/ml clozapine and its metabolite) and the bile. In the lights of these findings, it was concluded that the patient died from clozapine-induced eosinophilic hypersensitivity myocarditis. Drug-induced eosinophilic hypersensitivity myocarditis shou...
{"title":"Sudden Death Associated with Hypersensitivity Myocarditis Induced by Clozapine: An Autopsy Case","authors":"H. Eş, I. Melez, Ayse Ozgun, D. O. Melez, Ç. Kertmen, M. Cavlak","doi":"10.5455/BCP.20151216022322","DOIUrl":"https://doi.org/10.5455/BCP.20151216022322","url":null,"abstract":"ABSTRACTEosinophilic myocarditis is a rare cause of sudden unexpected death and characterized by eosinophilic infiltration in the myocardium. Clozapine is among the agents that can cause eosinophilic myocarditis. Our case is a 48 year-old female patient who was hospitalized in psychiatry inpatient unit and died unexpectedly on the 35th day of her hospitalization while on clozapine treatment. Even though the autopsy revealed an increased heart weight, fatty streaks on aorta, and thickening of epicardial fat tissue macroscopically, no pathological macroscopic features were noted in the myocardial cross sections. Eosinophilic myocarditis findings were found in the histopathological evaluation. Toxicological assessment revealed presence of clozapine in the blood (735ng/ml clozapine and its metabolite) and the bile. In the lights of these findings, it was concluded that the patient died from clozapine-induced eosinophilic hypersensitivity myocarditis. Drug-induced eosinophilic hypersensitivity myocarditis shou...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73648902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20160117032225
M. Cetin, G. Sayar
(2016). Risk Evaluation and Mitigation Strategy for Clozapine. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology: Vol. 26, No. 1, pp. 1-6.
(2016)。氯氮平的风险评估和缓解策略。临床精神药理学通报，第26卷，第1期，第1-6页。
{"title":"Risk Evaluation and Mitigation Strategy for Clozapine","authors":"M. Cetin, G. Sayar","doi":"10.5455/BCP.20160117032225","DOIUrl":"https://doi.org/10.5455/BCP.20160117032225","url":null,"abstract":"(2016). Risk Evaluation and Mitigation Strategy for Clozapine. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology: Vol. 26, No. 1, pp. 1-6.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73963184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20150223052448
G. Umut, M. Delice, A. Cansız, A. Can, E. Kurt, C. Evren
ABS TRACT: Clinical characteristics of euthymic bipolar disorder patients comorbid with alcohol and drug use disorders and psychometric properties of the assessment tools Objective: The primary objective of this study was to identify the frequency of alcohol and drug use disorder -abuse or dependence- (ADUD) in bipolar disorder patients who were followed in a specialized mood disorders unit and to investigate the clinical characteristics of the sample. Secondary aim of the study was to evaluate the psychometric properties of the scales related with alcohol and drug use disorder among bipolar patients in remission. Methods: Alcohol Use Disorders Identification Test (AUDIT), Michigan Alcoholism Screening Test (MAST), Drug Use Disorders Identification Test (DUDIT), and Drug Abuse Screening Test (DAST-10) were applied to 292 bipolar disorder patients in the euthymic state, diagnosed by using mood disorder and alcohol/drug use disorder modules of the Structured Clinical Interview Form for DSM-IV Axis I Disorders (SCID-I) and monitored in our Mood Disorders Center. Results: In our sample, frequency of bipolar disorder patients with ADUD was 6.16% (18/292). 15 of 18 patients with ADUD were men and 3 were women. ADUD in men (12.00%) was higher than in women (1.79%), and this difference was statistically significant (p<0.001). Alcohol use disorder frequency was detected as 5.14% in general (15/292), 9.60% in men (12/125) and 1.79% in women (3/167). The frequency of drug use disorder was found as 4.11% in general (12/292), 8.00% in men (10/125) and 1.19% in women (2/167). Proportion of depressive, manic, hypomanic, and mixed episodes did not differ between patients with ADUD and those without ADUD, whereas the proportion of total episodes was higher in patients with ADUD and difference was statistically significant (p=0.016). Conclusions: Frequency of bipolar disorder patients comorbid with ADUD followed up in our center was found to be lower than those reported in the literature.
{"title":"Clinical Characteristics of Euthymic Bipolar Disorder Patients Comorbid with Alcohol and Drug Use Disorders and Psychometric Properties of the Assessment Tools","authors":"G. Umut, M. Delice, A. Cansız, A. Can, E. Kurt, C. Evren","doi":"10.5455/BCP.20150223052448","DOIUrl":"https://doi.org/10.5455/BCP.20150223052448","url":null,"abstract":"ABS TRACT: Clinical characteristics of euthymic bipolar disorder patients comorbid with alcohol and drug use disorders and psychometric properties of the assessment tools Objective: The primary objective of this study was to identify the frequency of alcohol and drug use disorder -abuse or dependence- (ADUD) in bipolar disorder patients who were followed in a specialized mood disorders unit and to investigate the clinical characteristics of the sample. Secondary aim of the study was to evaluate the psychometric properties of the scales related with alcohol and drug use disorder among bipolar patients in remission. Methods: Alcohol Use Disorders Identification Test (AUDIT), Michigan Alcoholism Screening Test (MAST), Drug Use Disorders Identification Test (DUDIT), and Drug Abuse Screening Test (DAST-10) were applied to 292 bipolar disorder patients in the euthymic state, diagnosed by using mood disorder and alcohol/drug use disorder modules of the Structured Clinical Interview Form for DSM-IV Axis I Disorders (SCID-I) and monitored in our Mood Disorders Center. Results: In our sample, frequency of bipolar disorder patients with ADUD was 6.16% (18/292). 15 of 18 patients with ADUD were men and 3 were women. ADUD in men (12.00%) was higher than in women (1.79%), and this difference was statistically significant (p<0.001). Alcohol use disorder frequency was detected as 5.14% in general (15/292), 9.60% in men (12/125) and 1.79% in women (3/167). The frequency of drug use disorder was found as 4.11% in general (12/292), 8.00% in men (10/125) and 1.19% in women (2/167). Proportion of depressive, manic, hypomanic, and mixed episodes did not differ between patients with ADUD and those without ADUD, whereas the proportion of total episodes was higher in patients with ADUD and difference was statistically significant (p=0.016). Conclusions: Frequency of bipolar disorder patients comorbid with ADUD followed up in our center was found to be lower than those reported in the literature.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74807849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：